Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis

T. Limberger, M. Schlederer, K. Trachtová, I. Garces de Los Fayos Alonso, J. Yang, S. Högler, C. Sternberg, V. Bystry, J. Oppelt, B. Tichý, M. Schmeidl, P. Kodajova, A. Jäger, HA. Neubauer, M. Oberhuber, BS. Schmalzbauer, S. Pospisilova, H....

. 2022 ; 21 (1) : 89. [pub] 20220330

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22019098

BACKGROUND: Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated. METHODS: To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients. RESULTS: We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16INK4A. In addition, we observe a striking reduction in disease-free survival of patients with KMT2C-mutated prostate cancer. CONCLUSIONS: We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019098
003      
CZ-PrNML
005      
20240103104722.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-022-01542-8 $2 doi
035    __
$a (PubMed)35354467
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Limberger, Tanja $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u CBmed-Center for Biomarker Research in Medicine GmbH, 8010, Graz, Austria
245    10
$a KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis / $c T. Limberger, M. Schlederer, K. Trachtová, I. Garces de Los Fayos Alonso, J. Yang, S. Högler, C. Sternberg, V. Bystry, J. Oppelt, B. Tichý, M. Schmeidl, P. Kodajova, A. Jäger, HA. Neubauer, M. Oberhuber, BS. Schmalzbauer, S. Pospisilova, H. Dolznig, W. Wadsak, Z. Culig, SD. Turner, G. Egger, S. Lagger, L. Kenner
520    9_
$a BACKGROUND: Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated. METHODS: To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients. RESULTS: We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16INK4A. In addition, we observe a striking reduction in disease-free survival of patients with KMT2C-mutated prostate cancer. CONCLUSIONS: We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis.
650    _2
$a zvířata $7 D000818
650    _2
$a inhibitor p16 cyklin-dependentní kinasy $x genetika $x metabolismus $7 D019941
650    _2
$a DNA vazebné proteiny $x fyziologie $7 D004268
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a methyltransferasy $x genetika $7 D008780
650    _2
$a myši $7 D051379
650    _2
$a mutace $7 D009154
650    12
$a nádory prostaty $x metabolismus $7 D011471
650    _2
$a sekvenování exomu $7 D000073359
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schlederer, Michaela $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Trachtová, Karolina $u Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic $u Christian Doppler Laboratory for Applied Metabolomics, 1090, Vienna, Austria $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Garces de Los Fayos Alonso, Ines $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Yang, Jiaye $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Högler, Sandra $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Sternberg, Christina $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Institute of Biochemistry, Christian-Albrechts-University Kiel, 24118, Kiel, Germany
700    1_
$a Bystry, Vojtech $u Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic
700    1_
$a Oppelt, Jan $u Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic
700    1_
$a Tichý, Boris $u Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic $7 xx0312236
700    1_
$a Schmeidl, Margit $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Kodajova, Petra $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Jäger, Anton $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Neubauer, Heidi A $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Oberhuber, Monika $u CBmed-Center for Biomarker Research in Medicine GmbH, 8010, Graz, Austria
700    1_
$a Schmalzbauer, Belinda S $u Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic
700    1_
$a Dolznig, Helmut $u Institute of Medical Genetics, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Wadsak, Wolfgang $u CBmed-Center for Biomarker Research in Medicine GmbH, 8010, Graz, Austria $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Culig, Zoran $u Department of Urology, Innsbruck Medical University, 6020, Innsbruck, Austria
700    1_
$a Turner, Suzanne D $u Department of Pathology, University Cambridge, Cambridge, UK $u CEITEC, Masaryk University, Brno, Czech Republic
700    1_
$a Egger, Gerda $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Ludwig Boltzmann Institute Applied Diagnostics, 1090, Vienna, Austria
700    1_
$a Lagger, Sabine $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Kenner, Lukas $u Division of Experimental and Translational Pathology, Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u CBmed-Center for Biomarker Research in Medicine GmbH, 8010, Graz, Austria. lukas.kenner@meduniwien.ac.at $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria. lukas.kenner@meduniwien.ac.at $1 https://orcid.org/0000000321841338
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 21, č. 1 (2022), s. 89
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35354467 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20240103104718 $b ABA008
999    __
$a ok $b bmc $g 1822630 $s 1170341
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 21 $c 1 $d 89 $e 20220330 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
LZP    __
$a Pubmed-20220720
Back

Find record

Citation metrics

Archiving options